CD164 Antibody (502021) [Alexa Fluor® 350]

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CD164, also known as endolyn, MGC-24, and MUC-24, is an 80‑100 kDa transmembrane sialomucin protein that is expressed by epithelial cells, T and B cells, monocytes, hematopoietic progenitor cells, and activated basophils. CD164 functions as an adhesion molecule and a negative regulator of cell proliferation. A soluble isoform is generated by alternate splicing. CD164 was identified as a potential regulator of homing in a prostate cancer screening for CXCL12-responsive adhesion molecules (1). Within the ECD, human CD164 shares approximately 53% sequence identity with mouse and rat CD164.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array FAB5790U

• CD164 Antibodies
• CD164 Lysate
• CD164 Protein
• CD164 Proteins and Enzyme